Transcatheter Aortic Valve Implantation for Failed Surgical Bioprostheses

Patients with small bioprostheses or baseline stenosis were at increased risk for 1-year mortality.

When surgical bioprostheses develop structural deterioration, as evidenced by stenosis or regurgitation, repeat cardiac surgery carries increased risk. Transcatheter aortic valve replacement (TAVR) is a feasible alternative for some high-risk patients, but there is little data on long-term outcomes and in large numbers of patients. In this report from the Valve-in-Valve International Data (VIVID) Registry, investigators pooled data from 55 centers on 459 patients (mean age, 78) who developed bioprosthetic stenosis (39%), regurgitation (30%), or both (30%), and were treated with balloon-expandable (54%) or self-expanding (46%) TAVR devices. The median Society of Thoracic Surgeons (STS) predicted risk for mortality at 30 days was 10%.

Mortalit…

Reviewing Author

Howard C. Herrmann, MD

Disclosures

Consultant/Advisory BoardAffluent Medical; Artedrone; Caranx; Johnson & Johnson; Medtronic; Prolifagen; Wells Fargo

EquityMicrointerventional Devices, Inc.

RoyaltiesUniversity of Pennsylvania

Grant/Research SupportAbbott Vascular; Edwards Lifesciences; Johnson & Johnson; Medtronic

Editorial BoardsCatheterization and Cardiovascular Interventions; Journal of the American College of Cardiology; Circulation: Cardiovascular Interventions; JACC Cardiovascular Interventions; JACC Case Reports; JSCAI

Leadership Positions in Professional SocietiesHeart Valve Collaboratory (Scientific Committee Member, Chair of the Publications Committee)